Background
==========

Study 903 was a Phase III randomized double-blind (DB) 3 year study comparing TDF to stavudine (d4T) each in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected antiretroviral naïve patients. TDF was associated with durable efficacy and safety (better lipid profile, and less lipodystrophy and peripheral neuropathy). A subset of these patients now provides 10 years of longitudinal efficacy and safety data of TDF-containing once-daily HAART.

Methods
=======

Subjects in Argentina, Brazil, and the Dominican Republic who completed the 3 year DB period of study were eligible to roll-over into an open-label (OL) study (Study 903E) of the once-daily HAART regimen, TDF+3TC+EFV. At DB baseline 86 subjects were randomized to TDF (62% male, 70% white, mean age 33 yrs, mean HIV RNA=4.9 log~10~ c/mL, and mean CD4 count=299 cells/mm^3^). At OL baseline, 85 subjects (60% male, 64% white, mean age 37 yrs, median CD4=621 cells/mm^3^) switched from d4T to TDF. The results reflect only the period of TDF exposure.

Results
=======

See Table [1](#T1){ref-type="table"}

                                                              TDF/TDF^α^ (n=86)   D4T/TDF^α^ (n=85)
  ----------------------------------------------------------- ------------------- -------------------
  Weeks on HAART/TDF                                          480/480             480/336
                                                                                  
  HIV RNA \< 50 (copies/mL) at Week 480 (ITT, M=F)            63%                 64%
                                                                                  
  HIV RNA \< 50 (copies/mL) at Week 480 (ITT, M=E)            92%                 96%
                                                                                  
  Change in Mean (SD) CD4, cells/mm^3^                        545 (287)           180 (290)
                                                                                  
  Drug-related Adverse Events (Grades 1-4)                    66%                 46%
                                                                                  
  Change in Mean (SD) Creatinine Clearance, mL/min^β^         +2.5 (23.4)         -10.7 (22.6)
                                                                                  
  Median Limb Fat at Year 10, kg                              10.4                7.5
                                                                                  
  Percent Change in Mean (SD) Spine BMD^χ^                    -2.44 (5.08)^δ^     0.04 (4.72)
                                                                                  
  Percent Change in Mean (SD) Hip BMD                         -2.94 (4.95)^δ^     -1.86 (4.67)^δ^
                                                                                  
  Discontinuations during open-label extension                25 (29.1%)          19 (22.4%)
                                                                                  
  Adverse event                                               2 (2.3%)            2 (2.4%)
                                                                                  
  Suboptimal virologic response                               5 (5.8%)            1 (1.2%)
                                                                                  
  LTFU^ε^, Nonadherent, Pregnancy, Consent Withdrawn, Death   13 (15.1%)          9 (10.6%)
                                                                                  
  Other                                                       5 (5.8%)            7 (8.2%)

^α^TDF/TDF results measured from DB BL; d4T/TDF from OL baseline; ^β^Estimated by Cockcroft-Gault equation; ^χ^Bone mineral density; ^δ^p\<0.01 by Wilcoxon Signed Rank Test; ^ε^Lost to follow-up

Conclusions
===========

Antiretroviral-naïve subjects who received TDF-containing once-daily HAART for up to 10 years demonstrated sustained virologic and immunologic benefit, improved limb fat, stable renal function, and their BMD remained stable after a clinically insignificant decrease that occurred during the first year of TDF therapy.
